Indian's Aurobindo linked to buying $1.5 billion of Teva assets

7 July 2016

Reports have linked Indian drugmaker Aurobindo (BSE: 524804) to buying European assets of Israeli generics giant Teva Pharmaceutical Industries (NYSE: TEVA), with talk of a deal worth as much as $1.5 billion.

Teva is selling off assets to satisfy conditions laid down by anti-trust regulators on its proposed $40.5 billion purchase of the generics business of Ireland-incorporated Allergan (NYSE: AGN). These conditions state that the company must offload certain assets to avoid the merged entity breaching competition requirements.

In recent weeks a number of companies, including India’s Zytus Cadila and Dr Reddy’s Laboratories (BSE: 500124), have been swooping to buy up these products, and Aurobindo is the latest to show interest, according to Bloomberg.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK